Hydrazine – Addendum: withdrawal of EKA
Assessment Values in Biological Material – Translation of the German version from 2024
Annette Greiner1Gabriele Leng2
Hans Drexler3 (Head of the working group “Assessment Values in Biological Material” of the Permanent Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area, Deutsche Forschungsgemeinschaft)
Andrea Hartwig4 (Chair of the Permanent Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area, Deutsche Forschungsgemeinschaft)
MAK Commission5
1 Regierung von Mittelfranken, Gewerbeaufsichtsamt, Roonstraße 20, 90429 Nürnberg, Germany
2 40699 Erkrath, Germany
3 Friedrich-Alexander-Universität Erlangen-Nürnberg, Institute and Outpatient Clinic of Occupational, Social, and Environmental Medicine, Henkestraße 9–11, 91054 Erlangen, Germany
4 Institute of Applied Biosciences, Department of Food Chemistry and Toxicology, Karlsruhe Institute of Technology (KIT), Adenauerring 20a, Building 50.41, 76131 Karlsruhe, Germany
5 Permanent Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area, Deutsche Forschungsgemeinschaft, Kennedyallee 40, 53175 Bonn, Germany
Abstract
The German Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area (MAK Commission) re-evaluated the data for the derivation of exposure equivalents for carcinogenic substances (EKA) for hydrazine [302-01-2]. Relevant studies were identified from a literature search. The EKA for hydrazine in air and hydrazine in urine as well as for hydrazine in plasma, established in 1991, were essentially based on unpublished data. Moreover, relevant studies appeared since the last evaluation, which point to major limitations for the use of EKA for hydrazine in urine and plasma. Therefore, the EKA are withdrawn.
